AstraZeneca's Brilinta Fails Arterial Disease Drug Trial
AstraZeneca cut its sales target for prescription blood-thinning medicine Brilinta after it failed to show a benefit over standard treatment in peripheral artery disease in a large clinical trial.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news
More News: AstraZeneca | Clinical Trials | Health | Peripheral Vascular Disease (PVD) | Pharmaceuticals